@article{f49a83724b0b4f9ea0127da053c38b66,
title = "Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial",
abstract = "Introduction: Hearing impairment is highly prevalent and independently associated with cognitive decline. The Aging and Cognitive Health Evaluation in Elders study is a multicenter randomized controlled trial to determine efficacy of hearing treatment in reducing cognitive decline in older adults. Clinicaltrials.gov Identifier: NCT03243422. Methods: Eight hundred fifty participants without dementia aged 70 to 84 years with mild-to-moderate hearing impairment recruited from four United States field sites and randomized 1:1 to a best-practices hearing intervention or health education control. Primary study outcome is 3-year change in global cognitive function. Secondary outcomes include domain-specific cognitive decline, incident dementia, brain structural changes on magnetic resonance imaging, health-related quality of life, physical and social function, and physical activity. Results: Trial enrollment began January 4, 2018 and is ongoing. Discussion: When completed in 2022, Aging and Cognitive Health Evaluation in Elders study should provide definitive evidence of the effect of hearing treatment versus education control on cognitive decline in community-dwelling older adults with mild-to-moderate hearing impairment.",
keywords = "Clinical trials, Cognition, Dementia, Epidemiology, Hearing, Longitudinal study, Memory, Presbycusis",
author = "{ACHIEVE Investigators} and Deal, {Jennifer A.} and Goman, {Adele M.} and Albert, {Marilyn S.} and Arnold, {Michelle L.} and Sheila Burgard and Theresa Chisolm and David Couper and Glynn, {Nancy W.} and Theresa Gmelin and Hayden, {Kathleen M.} and Thomas Mosley and Pankow, {James S.} and Nicholas Reed and Sanchez, {Victoria A.} and {Richey Sharrett}, A. and Thomas, {Sonia D.} and Josef Coresh and Lin, {Frank R.}",
note = "Funding Information: The Aging and Cognitive Health Evaluation in Elders (ACHIEVE) Study is supported by the National Institute on Aging (NIA) R01AG055426 , with previous pilot study support from the NIA 1R34AG046548-01A1 and the Eleanor Schwartz Charitable Foundation, in collaboration with the Atherosclerosis Risk in Communities (ARIC) Study, supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data in ARIC is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, and 2U01HL096917 from the National Institute of Health ( NHLBI , National Institute of Neurological Disorders and Stroke, NIA , and National Institute on Deafness and Other Communication Disorders), and with previous brain magnetic resonance examinations funded by R01-HL70825 from the NHLBI . The authors thank the staff and participants of the ACHIEVE and ARIC studies for their important contributions. J.A.D. is supported by NIA K01AG23291 . Publisher Copyright: {\textcopyright} 2018 The Authors",
year = "2018",
month = jan,
day = "1",
doi = "10.1016/j.trci.2018.08.007",
language = "English (US)",
volume = "4",
pages = "499--507",
journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",
issn = "2352-8737",
publisher = "Elsevier Inc.",
}